MedTrace Logo

Serum TAM Receptor Tyrosine Kinase Ligands in Acute Pancreatitis

NCT07023055 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 896

Last updated 2025-06-22

No results posted yet for this study

Summary

AXL and MERTK are homologous members of the TAM (TYRO3, AXL, MERTK) receptor tyrosine kinase family. They function as critical regulators of antiviral immunity, autoimmune responses, and tumor microenvironment modulation through their bridging ligands, GAS6 (Growth Arrest-Specific 6) and PROS1 (Protein S). These receptors serve as damage sensors that negatively regulate inflammation, promote tissue repair/remodeling, and modulate fibrotic processes in chronic inflammatory conditions. Building upon our previous work demonstrating the pivotal role of the AXL/MERTK signaling axis in AP pathogenesis - particularly in pancreatic necrosis regulation, this clinical study seeks to evaluate the prognostic value of the TAM receptor ligands GAS6 and PROS1 as biomarkers for predicting AP severity.

Conditions

  • Acute Pancreatic Necrosis
  • Acute Pancreatitis (AP)

Sponsors & Collaborators

  • The first affiliated Hospital of Nanjing Medical University, Jiangsu Province

    collaborator UNKNOWN

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2025-03-01
Completion
2025-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07023055 on ClinicalTrials.gov